Postmenopause

Among long term survivors of primary breast cancer, a high level of exercise pre-diagnosis significantly reduced risk for CV events after diagnosis.

Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily teriparatide followed by one subcutaneous injection of denosumab experienced a moderate gain in cortical bone mineral density at 18 months that was not observed among similar women who received the standard regimen of 18 months of teriparatide followed by 18 months of denosumab, according to findings published in the Journal of Bone and Mineral Research.

Sex steroid levels, particularly levels of estrone and testosterone, vary widely among older women, with higher levels of testosterone possibly indicating lower risk for disease, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Radius Health has initiated enrollment for a phase 3 clinical trial to assess the safety and efficacy of a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture, the company announced in a press release.

Postmenopausal women with type 2 diabetes reported more sleep-related symptoms, such as frequent urination, excessive thirst and anxiety, and they rated those symptoms as more severe when compared with postmenopausal women without diabetes, according to findings published in Menopause.

PHILADELPHIA — Compared with postmenopausal women using FDA-approved hormone therapy, those treated with estradiol and/or testosterone pellet therapy experienced six times the number adverse side effects, including abnormal uterine bleeding and subsequent hysterectomy, according to findings from a retrospective cohort study.